Reagent solutions for targeted protein degradation

Proteolysis Targeting Chimaeras (PROTACs) are innovative small molecules that revolutionize drug discovery. They consist of two binding regions—one recognizing an E3 ubiquitin ligase and the other a protein of interest (POI). When both regions bind, a ternary complex forms, leading to ubiquitination and subsequent proteasomal degradation of the POI. Unlike traditional drugs that inhibit the proteasome, PROTACs directly target the POI, potentially offering more effective cancer treatments.

Explore Revvity’s reagent technologies for PROTAC® research: 1. Biochemical Assays: Investigate GPCR research, cell signaling, and protein-protein interactions. 2. Immunodetection Kits: Obtain fast and accurate results using Alpha and HTRF assay technologies. Discover the future of drug discovery with PROTACs.

For research use only. Not for use in diagnostic procedures.